Latest Operating Costs News

Nova Eye Medical has delivered solid FY25 results, meeting sales guidance outside China and achieving six consecutive halves of growth in the US market. The company also improved gross margins and reduced cash burn, setting an optimistic tone for FY26 with breakeven EBITDA guidance.

Savannah Goldfields Limited has announced a $15 million equity raising through a placement and conditional placement, offering free attaching options subject to shareholder approval. The capital raise aims to strengthen the company’s financial position and support its operational restart plans.

US Masters Residential Property Group reports a half-year profit and advances its ambitious asset sales program, while navigating a significant US tax structure change and mixed market conditions.

Invion Limited posted a $8.8 million loss for FY25, marking a 56.5% increase, while advancing clinical trials and securing fresh capital. The biotech faces a going concern warning amid ongoing development and funding challenges.

OMG Group has raised $2 million through a share placement to boost inventory and capitalise on growing demand from major Australian retailers and ecommerce channels.

Ark Mines Ltd is fast-tracking its Sandy Mitchell rare earths project in Queensland, backed by a $4.5 million investment from the Queensland Investment Corporation and targeting production by late 2027.

KPMG has delivered an unqualified audit opinion on Bathurst Resources Limited’s FY2025 financial statements, while highlighting significant judgment areas around mining asset recoverability and rehabilitation provisions.

Karoon Energy has significantly upgraded its Baúna Project 2P Reserves by 35%, extending the field’s economic life by seven years to 2039, driven by the recent FPSO acquisition and improved reservoir performance.

Kina Securities Limited reported a robust 37% jump in statutory net profit after tax for the half year ended June 2025, driven by solid revenue growth and expanding loan portfolios. The bank also declared a higher interim dividend, reflecting confidence in its financial strength.

Proteomics International Laboratories reported a 26% increase in losses for FY2025, driven by higher operational costs as it advances its Promarker® diagnostic pipeline. Despite an 8% rise in revenue from ordinary activities, total income slipped 2%, underscoring ongoing commercialisation challenges.

PlaySide Studios reported a significant revenue drop and EBITDA loss in FY25, driven by declines in original IP sales. However, the company is banking on new game launches and cost-cutting measures to fuel a turnaround in FY26.

PlaySide Studios reported a 25% revenue decline to $48.7 million for FY25, resulting in a $12.1 million net loss. The company is banking on new game launches and cost savings to reverse the downturn in FY26.